Innovative Targeting Solutions to Present Update on GLP1R Agonist Drug Programs
December 4, 2014
Burnaby, B.C., Canada. December 4th, 2014: Innovative Targeting Solutions Inc. (ITS) a pioneer in novel protein engineering technologies will be providing an update regarding both its GLP1R agonist and GLP1R/Glucagon dual agonist programs on December 8th, 2014 during the Antibody Engineering and Therapeutics conference next week.
Dr. Michael Gallo’s presentation will include the company’s work engineering heavy chain only antibodies (HCAbs) and the different strategies deployed using the company’s HuTARG technology to increase GLP1 receptor agonist potency of the company’s first-in-class peptide-grafted antibodies. The ability to generate large de novo libraries of protein variants and screen them for function at the single cell level at the scale of 100s of millions of cells is unprecedented and demonstrates the unique competitive advantage of the technology to generate antibody solutions to difficult targets.
The ability to engineer proteins in a mammalian system provides for opportunities not possible with traditional yeast or phage display with regards to function and native confirmation of complex membrane targets and makes ITS’ HuTARG technology much more than just another antibody technology and establishes Innovative Targeting Solutions a leader in the generation of novel Biologics and future medicines.
About Innovative Targeting Solutions Inc. Founded in 2008, Innovative Targeting Solutions Inc. is a privately‐held company that has developed the HuTARG technology a next generation protein engineering platform for the generation and maturation of fully human antibody therapeutics. The HuTARG technology is a fully mammalian technology that generates antibody diversity in vitro via RAG1/RAG2 mediated V(D)J recombination. For more information please visit www.innovativetargeting.com